CLINICAL ASSESSMENT OF ALAMBUSHADI CHURNA AND DWIPANCHMULADHYA TAIL VASTI IN THE MANAGEMENT OF AMAVATA VIS-A-VIS RHEUMATOID ARTHRITIS by Sunil Kumar* & O.P.Singh
AYUSHDHARA             ISSN: 2393-9583 (P)/ 2393-9591 (O) 
 An International Journal of Research in AYUSH and Allied Systems 
 AYUSHDHARA | July - August 2019 | Vol 6 | Issue 4  2286 
 
     
 
 
CLINICAL ASSESSMENT OF ALAMBUSHADI CHURNA AND DWIPANCHMULADHYA TAIL VASTI IN 
THE MANAGEMENT OF AMAVATA VIS-A-VIS RHEUMATOID ARTHRITIS  
Sunil Kumar1*, O.P.Singh2 
*1Jr 3nd, 2Professor, Dept. of Kayachikita, IMS, B.H.U., Varanasi, Uttar Pradesh, India. 
 
KEYWORDS: Alambusadi 
churna, Dwipanchmuladi tail, 
Vasti, Aamvata, Rheumatoid 
Arthritis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ABSTRACT 
Amavata is a chronic immune inflammatory systemic disorder mainly 
affecting synovial joints, caused due to formation of Ama and its 
association with vitiated Dosha and deposition in Shleshma sthana i.e. 
joints. Clinical features of Amavata resembles with Rheumatoid Arthritis, 
it poses a challenge for the physician owing to its chronicity, morbidity 
and complications. The treasure of Ayurveda therapeutics has laid out 
detailed treatment line for Amavata. Hence to establish a firm scientific 
basis for classical Ayurvedic formulation is now being felt. Keeping in 
view the above concepts, the research work entitled Clinical Assessment 
of Alambushadi Churna and Dwipanchmuladhya Tail Vasti in the 
Management of Amavata vis-a-vis Rheumatoid Arthritis.  
The sample of 60 patients presenting with classical signs and symptoms 
of Aamavata according to Ayurvedic classics, after subjection to modern 
parameters were subdivided randomly into four groups. Out of 60 
patients only 51 patients completed the follow up study in which group A 
(Alambushadi churn orally) consist of 13 patients, group B (Matra Vasti 
by Dwipanchmuladhya Tail), consist of 12 patients group C (Alambushadi 
Churn orally) consist of 13 patients and group D (methotrexate Folic 
Acid) consist of 13 patients.  
The research work and the Ayurvedic management schedule of Matra 
Vasti and Alambushadi churna can be used in the chronic as well as acute 
patients of Amavata with fruitful results. 
 
INTRODUCTION 
 Ayurveda is a system of healing unlike any 
other, offering a unique approach to health care in 
the form of self-discovery. Occurrence of Amavata[1] 
on large scale is one of the outcomes of modification 
of the dietary habits, social structure, life style, and 
environment change. It is a chronic condition 
involving loss of mobility and enduring pain of the 
joints with some swelling of the synovial joints. 
Persistent synovial inflammation often causes 
cartilage damage and bone erosions that badly 
disturbs joint integrity, as an outcome of which one 
third of patients suffer from working disability by 
five years. RA[2] is correlated with Amavata 
mentioned in Ayurveda. Inspite of the description of 
multiple drug therapy on Amavata in different 
classics of Ayurveda, potential and durable results 
are not found due to non-removal of the basic 
cause. Hence, special emphasis should be put into 
searching for a standard and suitable drug for 
Amavata. Hence to establish a firm scientific basis 
for classical ayurvedic formulation is now being felt. 
Keeping in view the above concepts, the research 
work entitled "Clinical Assessment of Alambushadi 
Churna and Dwipanchmuladhya Tail Vasti in the 
Management of Amavata vis-a–vis Rheumatoid 
Arthritis" was carried out in Department of 
Kayachikitsa, S.S.Hospital, B.H.U. Varanasi. In 
Amavata, Vata is dominant Dosha and Ama is the 
chief pathogenic factor. Ancient Acharyas of 
Ayurveda have described sequential employment of 
Deepana[3], Pachana[4], Shodhana[5] and Shamana[6] 
therapies in the management of Amavata. The 
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formulations under trial in this study, Alambushadi 
churna[7] and Matra Vasti with Dwipanchmuladhya 
Taila[8] are described in the Ayurvedic text in 
Chakradatta Amavataadhikara and in Bhavprakash 
Amavatadhikara respectively. In present study Vasti 
Karma[9] is selected as Shodhana Chikitsa. It is 
directly mentioned in the Chikitsa Sutra of Amavata 
by Chakradatta and is considered as Ardha 
Chikitsa[10] in Ayurvedic texts. Alambushadi churna 
is selected as Shaman Chikitsa. It performs Deepan 
and Pachan karma in the patient of Amavata. The 
selected trial drug Alambusadi churna is mentioned 
by Acharya Chakrapani in Chakradatta in reference 
to Amavata Rogadhikara and Matra Vasti is 
mentioned by Bhavprakash in Amavataadhikara in 
reference of Amavata with the emphasis that they 
destroy the disease from its root. Alambushadi 
churna is given by oral rout and MatraVasti with 
Dwipanchmuladhya Taila by anus route.  
DESIGN OF THE STUDY 
The study is open-labelled, randomized 
clinical study.  
AIMS AND OBJECTIVES 
 To clinically assess the efficacy of Alambusadi 
churna in the management Amavata vis-à-vis 
Rheumatoid arthritis. 
 To clinically assess the efficacy of 
Dwipanchmuladhya Taila Vasti in the 
management Amavata vis-à-vis Rheumatoid 
arthritis. 
 To clinically assess the efficacy of 
Dwipanchmuladhya taila vasti and Alambusadi 
churna in the management of Amavata. 
 To compare the clinical efficacy of Interventional 
group and Control group in the management 
Amavata vis-à-vis Rheumatoid arthritis. 
MATERIAL AND METHODS 
Preparation of Drugs 
Alambushadi Churna was prepared 
following the SOP norms as follows- Starting from 
Lajjalu, all the drugs upto Trivrita in given quantity 
were mixed and made into fine Churna (powder). 
Table 1: Contents of Alambushadi Churna[11] 
S.No. Name Botanical Name Quantity 
1. Lajjalu Mimosa pudica 1 part 
2. Gokshur Tribulus terrestris 2 part 
3. Amalaki Emblica officinalis 3 part 
4. Haritki Terminalia chebula 4 part 
5. Bibhitki Terminalia bellirica 5 part 
6. Sunthi Zingiber officinalis 6 part 
7. Guduchi Tinospora cardifolia 7 part 
8. Trivrita Operculina turpethum 28 part 
Table 2: Contents of Dwipanchmuladhya Tail Vasti[12] 
S.No. Name Botanical name Quantity 
1 Belmultwak Aegle marmelos 1 part 
2 Gambharimultwak Gmelia arborea 1 part 
3 Patalamul) Stereospermum suaveolens 1 Pala  
4 Sonapatha Oroxylum indicum 1 part 
5 Arnimul Premna mucronata 1 part 
6 Shalparni Desmodium gangeticum 1 part 
7 Prishnaiparni Uraria picta 1 part 
8 ChotKatari Solanum surattense 1 part 
9 BadiKatari Solanum indicum 1 part 
10 Gokshur Tribulus terrestris 1 part 
11 TilaTaila Sesame oil Q.S. 
Method of Preparation  
All the crude drugs were available in pharmacy of Rasasastra department. All drugs were tested for 
their quality and authenticity. Dwipanchmuladhya taila was prepared according to Ayurvedic Classic Text 
Book. 
Time of Administration: It is a Matra vasti that can be given after the meals (Bhukte Cha Api Pradiyate). 
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Method of Administration of Vasti: Patient was advised to lie on an even Vasti table in left lateral position 
with straight body and left hand kept as pillow. His right leg was folded at knee joint and made to rest flat 
over the left leg. Patient’s anus and rubber catheter was smeared with cutting substance like tail. 
Rubber catheter was introduced in anus by its 4-6cm part slowly. Vasti dravya was taken in Asepto 
pump and forced slowly in one push then after Rubber catheter was taken out slowly. 
Selection of Cases: Total 60 patients of Amavata were randomly selected for the present study, from the 
Kayachikitsa OPD and IPD of Sir Sunder Lal Hospital, Institute of Medical Sciences, Banaras Hindu University, 
Varanasi. The case selection was random regardless of age, sex, occupation and religion. Both acute and 
chronic phase of Amavata patients were taken for the study, following the criteria of the diagnosis of 
Rheumatoid Arthritis in modern medicine and the clinical features of Amavata described in Madhava 
Nidana. 
Inclusion Criteria 
 Age between 20-60 years. 
 Patient willing to participate for this trial. 
 Diagnosed cases of Amavata based on symptoms and signs described in Nidana and EULAR 2010. 
 Sero positive and sero negative both cases are included. 
 Patients with H/O 1-5 years with established disease.  
Exclusion Criteria 
 Not willing patients. 
 Patients should not be less than 20 years and more than 60 years. 
 Patients of Rheumatic Arthritis, Gouty Arthritis, Septic Arthritis, Osteoarthritis and Ankylosing 
Spondylitis. 
 HIV, Tuberculosis, Hypertension, D.M. and other systemic problem. 
 Pregnant and lactating women. 
 Patients with major complication are also excluded. 
Diagnostic Criteria for Rheumatoid Arthritis 
• Eular Criteria[13]  
• Eular classification system is a score-based algorithm for RA that incorporates the following 4 factors-  
• Joint involvement  
• Serology test results  
• Acute-phase reactant test results  
• Patient self-reporting of the duration of signs and symptoms 
• The maximum number of points possible is 10. A classification of definitive RA requires a score of 6/10. 
• EULAR 2010  
Joint Involvement  1 Large Joint (Shoulder, Elbow, Hip, Knee, Ankle) 0 
 2-10 Large joints  1  
1-3 Small joints (MCP, PIP, Thumb, IP, MTP, wrist)  2  
4-10 Small joints  3  
>10 joints (atleast 1 small joint)  5  
Serology  Negative RF and negative Anti CCP Antibody  0  
Low positive RF or low positive Anti CCP Antibody  2  
 (</=3 times of upper limit of normal value)  
High positive RF or high positive Anti CCP Antibody  3  
 (>3 times of upper limit of normal value)  
Acute phase reactants  Normal CRP and normal ESR  0  
Abnormal CRP and abnormal ESR  1  
Duration of symptoms  <6 week  0  
>6 week  1  
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Diagnosis of Amavata was made on the basis of symptom of Amavata described in Ayurvedic text book.  
 Sandhishoola (Pain) 
 Sanshishotha (Swelling) 
 Sandhigraha (Stiffness) 
 Sparsha-asahatva (Tenderness) 
 Sashabdasandhi (Crepitus) 
Physical Examination: Under the physical examination patient's general condition, pulse rate, blood 
pressure, pallor, icterus, cyanosis, lymphadenopathy, and body weight were recorded at the basal level and 
at each successive follow ups. 
Study Design             
 The sample of 60 patients presenting with classical signs and symptoms of Aamavata according to 
Ayurvedic classics, after subjection to modern parameters were subdivided randomly into four groups. Out 
of 60 patients only 51 patients completed the follow up study in which group A consist of 13 patients, group 
B consist of 12 patients, group C consist of 13 patients and group D consist of 13 patients. 
Registration and Allocation of 60 Patients in different groups 
Group A (N=15) Group B (N=15) Group C (N=15) Group D (N=15) 
No. of patients completed 
trial (N=13) 
No. of patients 
completed trial (N=12) 
No. of patients completed 
trial (N=13) 
No. of patients 
completed trial (N=13) 
Drop out patients (N=2) Drop out patients (N=3) Drop out patients (N=2) Drop out patients (N=2) 
Not following 
instructions (N=1) 
Patient improvement was 
slow (N=1) 
Not following 
instructions (N=2) 
Patient further 
diagnosed with TB (N=1) 
Not following 
instructions (N=1) 
Patients not coming for 
regular follow up (N=1) 
Not following 
instructions (N=2) 
Group A 
No. of patients Medicine Dosage Duration & follow up 
13 Alambushadi churn 
(orally) 
5g BD with lukewarm 
water 
90 Days with a follow 
up every 1 Month 
Group B 
No. of patients Medicine Dosage Duration & follow up 
12 Matra Vasti by 
Dwipanchmuladhya Tail 
60ml/day for 7 days 90 Days with a follow up 
every 1 Month 
Group C 
No. of patients Medicine Dosage Duration & follow up 
13 Alambushadi Churn (orally) 5g BD with lukewarm 
water 
90 Days with a follow up 
every 1 Month 
 Matra Vasti by 
Dwipanchmuladhya Tail 
60ml/day for 7 days 90 Days with a follow up 
every 1 Month 
Group D  
No. of patients Medicine Dosage Duration & follow up 
13 [14] methotrexate 
Folic Acid 
5mg OD weekly 
5mg OD Weekly 
90 Days with a follow up 
every 1 Month. 
Parameters for the Assessment of Improvement  
Clinical Assessment of Amavata  
Assessment of Functional Status  
Walking time: This test provides functional status of hip, knee, ankle and smaller joints of the lower limbs. 
In the present study a distance of 25ft was fixed for the purpose, and grading was given  
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0 =15 - 20 sec 
1 = 21- 30 sec 
2 = 31- 40 sec 
3 = > 40 sec 
Grip power and pressing power: The functional status of wrist joints, metacarpophalangeal joints and 
interphalangeal joints was assessed by measuring of pressing power and grip power.  
0 = 200mmHg 
1 =198 - 120mmHg 
2 =118 - 70mmHg 
3 =<70mmHg 
Foot pressure: To have an objective view of the functional capacity of the legs, foot pressure was recorded 
by the ability of the patients to press a weighing machine. 
0 = 25- 20 kg 
1 = 20-16 kg 
2 = 15- 10 kg 
3 = 10 kg 
Clinical Assessment of the Disease  
Clinical assessment of the disease, its severity, extent and grades of inflammation were objectively 
done in terms of pain swelling tenderness, deformity, general function capacity and stiffness of the joints. 
Pain: It is determined by intensity of pain on passive movement and rate of analgesic drug requirement. 
0 No pain 
1 Pain complaints but tolerable 
2 Pain complaints difficult to tolerate and taking analgesic once a day. 
3 Intolerable pain and taking analgesics two times a day 
4 Intolerable pain and taking analgesics more than two times in a day. 
Swelling 
0  No swelling 
1  Feeling of swelling + Heaviness 
2 Apparent swelling 
3  Huge (Synovial effusion) swelling 
Stiffness 
0 No stiffness 
1 20% limitation of normal range of mobility 
2 50% limitation of mobility 
3 75% or more reduction of normal range of movement 
General Function Capacity 
0  Complete ability to carry on all routine duties 
1 Frequent normal activity despite slight difficulty in joint movement 
2 Few activities are persisting but patient/attendant can take care of him or herself 
3 Patient is totally bed ridden 
Tenderness 
0 No tenderness 
1 Mild tenderness 
2 Moderate tenderness 
3 Severe tenderness 
Laboratory Profile  
Hematological investigations           
CBC, TLC, HGB, PLT, LFT, RFT, RBS, LIPID profile, Anti CCP and RA 
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OBSERVATION & RESULT 
Table 1: Pain 
Group Score BT F1 F2 AT Within the group 
comparison 
Friedman Test 
No. of 
pt. 
% No. of 
pt. 
% No. 
of pt. 
% No. of 
pt. 
% 
A 0 0 0.0 0 0.0 0 0.0 0 0.0 2=37.554 
p=0.000 1 0 0.0 0 0.0 0 0.0 4 30.8 
2 0 0.0 0 0.0 6 46.2 5 38.5 
3 5 38.5 6 46.2 7 53.8 4 30.8 
4 8 61.5 7 53.8 0 0.0 0 0.0 
B 0 0 0.0 0 0.0 0 0.0 0 0.0 2=32.556 
p=0.000 1 0 0.0 0 0.0 0 0.0 5 41.7 
2 0 0.0 2 16.7 5 41.7 6 50.0 
3 3 25.0 7 58.3 7 58.3 1 8.3 
4 9 75.0 3 25.0 0 0.0 0 0.0 
C 0 0 0.0 0 0.0 0 0.0 5 38.5 2=37.331 
p=0.000 1 0 0.0 0 0.0 3 23.1 7 53.8 
2 0 0.0 4 30.8 8 61.5 1 7.7 
3 6 46.2 8 61.5 2 15.4 0 0.0 
4 7 53.8 1 7.7 0 0.0 0 0.00 
D 0 0 0.0 0 0.0 0 0.0 8 61.5 2=37.984 
p=0.000 1 0 0.0 0 0.0 7 53.8 5 38.5 
2 0 0.0 2 15.4 6 46.2 0 0.0 
3 6 46.2 9 69.2 0 0.0 0 0.0 
4 7 53.8 2 15.4 0 0.0 0 0.0 
Inter group 
comparison among 
the groups Kruskal 
Wallis test 
2=1.515 
P=0.679 
2=9.981 
P=0.019 
 (S) 
2=21.472 
P=0.000 
 (HS) 
2=27.265 
P=0.000 
 (HS) 
 
Table 2: Swelling 
Group Score BT F1 F2 AT Within the group 
comparison 
Friedman Test 
No. of 
pt. 
% No. of 
pt. 
% No. of 
pt. 
% No. of 
pt. 
% 
A 0 0 0.00 0 0.00 0 0.00 3 23.1 2=35.605 
p=0.000 1 0 0.00 0 0.00 4 30.8 9 69.2 
2 4 30.8 7 53.8 9 69.2 1 7.7 
3 9 69.2 6 46.2 0 0.00 0 0.00 
B 0 0 0.00 0 0.00 0 0.00 1 8.3 2=30.810 
p=0.000 1 0 0.00 0 0.00 5 41.7 8 66.7 
2 3 25.0 9 75.0 7 58.3 3 25.0 
3 9 75.0 3 25.0 0 0.00 0 0.00 
C 0 0 0.00 0 0.00 0 0.00 9 69.2 2 =36.378 
p=0.000 1 0 0.00 0 0.00 9 69.2 4 30.8 
2 5 38.5 11 84.6 4 30.8 0 0.00 
3 8 61.5 2 15.4 0 0.00 0 0.00 
D 0 0 0.00 0 0.00 0 0.00 8 61.5 2=35.845 
p=0.000 1 0 0.00 1 7.7 10 76.9 5 38.5 
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2 5 38.5 9 69.2 3 23.1 0 0.00 
3 8 61.5 3 23.1 0 0.00 0 0.00 
Inter group 
comparison among the 
groups Kruskal Wallis 
test 
2=0.707 
P=0.872 
2=3.478 
P=0.324 
2=7.383 
P=0.61 
2=15.605 
P=0.001 
 
Table 3: Joint Stiffness 
Group Score BT F1 F2 AT Within the group 
comparison 
Friedman Test 
No. 
of pt. 
% No. of 
pt. 
% No. of 
pt. 
% No. of 
pt. 
% 
A 0 0 0.00 0 0.00 0 0.00 1 7.7 2=34.189 
p=0.000 1 0 0.00 0 0.00 5 38.5 9 69.2 
2 4 30.8 9 69.2 8 61.5 3 23.1 
3 9 69.2 4 30.8 0 0.00 0 0.00 
B 0 0 0.00 0 0.00 0 0.00 2 16.7 2=28.372 
p=0.000 1 0 0.00 1 8.3 8 66.7 8 66.7 
2 6 50.0 10 83.3 3 25.0 2 16.7 
3 6 50.0 1 8.3 1 8.3 0 0.00 
C 0 0 0.00 0 0.00 0 0.00 5 38.5 2=34.902 
p=0.000 1 0 0.00 1 7.7 9 69.2 8 61.5 
2 7 53.8 9 69.2 4 30.8 0 0.00 
3 6 46.2 3 23.1 0 0.00 0 0.00 
D 0 0 0.00 0 0.00 0 0.00 5 38.5 2= 35.690 
p=0.000 1 0 0.00 1 7.7 11 84.6 8 61.5 
2 4 30.8 10 76.9 2 15.4 0 0.00 
3 9 69.2 2 15.4 0 0.00 0 0.00 
Inter group 
comparison among 
the groups Kruskal 
Wallis test 
2=2.363 
P=0.001 
2=2.716 
P=0.438 
2=5.866 
P=0.118 
2=8.345 
P=0.039 
 
Table 4: Walking Time 
Group Score BT F1 F2 AT Within the group 
comparison 
Friedman Test 
No. 
of pt. 
% No. of 
pt. 
% No. of 
pt. 
% No. of 
pt. 
% 
A 0 0 0.00 0 0.00 0 0.00 1 7.7 2=34.091 
p=0.000 1 0 0.00 0 0.00 8 61.5 11 84.6 
2 5 38.5 11 84.6 5 38.5 1 7.7 
3 8 61.5 2 15.4 0 0.00 0 0.00 
B 0 0 0.00 0 0.00 0 0.00 4 33.3 2=32.774 
p=0.000 1 0 0.00 0 0.00 9 75.0 8 66.7 
2 6 50.0 11 91.7 3 25.0 0 0.00 
3 6 50.0 1 8.3 0 0.00 0 0.00 
C 0 0 0.00 0 0.00 2 15.4 10 76.9 2=35.619 
p=0.000 1 1 7.7 3 23.1 9 69.2 3 23.1 
2 6 46.2 10 76.9 2 15.4 0 0.00 
3 6 46.2 0 0.00 0 0.00 0 0.00 
D 0 0 0.00 0 0.00 0 0.00 10 76.9 2=36.885 
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1 0 0.00 1 7.7 11 84.6 3 23.1 p=0.000 
2 5 38.5 11 84.6 2 15.4 0 0.00 
3 8 61.5 1 7.7 0 0.00 0 0.00  
Inter group 
comparison 
among the groups 
Kruskal Wallis test 
2=1.257 
P=0.739 
2=6.771 
P=0.80 
2=3.901 
P=0.272 
2=18.437 
P=0.000 
Table 5: Grip Power 
Group Score BT F1 F2 AT Within the group 
comparison 
Friedman Test 
No. of 
pt. 
% No. of 
pt. 
% No. 
of pt. 
% No. 
of pt. 
% 
A 0 0 0.00 0 0.00 0 0.00 1 7.7 2=33.956 
p=0.000 1 0 0.00 1 7.7 6 46.2 12 92.3 
2 5 38.5 10 76.9 7 53.8 0 0.00 
3 8 61.5 2 15.4 0 0.00 0 0.00 
B 0 0 0.00 0 0.00 0 0.00 1 8.3 2=31.912 
p=0.000 1 0 0.00 0 0.00 8 66.7 10 83.3 
2 6 50.0 11 91.7 4 33.2 1 8.3 
3 6 50.0 1 8.3 0 0.00 0 0.00 
C 0 0 0.00 0 0.00 0 0.00 7 53.8 2=35.619 
p=0.000 1 0 0.00 1 7.7 11 84.6 6 46.20 
2 6 46.2 12 92.3 2 15.4 0 0.00 
3 7 53.8 0 0.00 0 0.00 0 0.00 
D 0 0 0.00 0 0.00 0 0.00 7 53.8 2=35.542 
p=0.000 1 0 0.00 2 15.4 8 61.5 6 46.2 
2 5 38.5 10 76.9 5 38.5 0 0.00 
3 8 61.5 1 7.7 0 0.000 0 0.00 
Inter group 
comparison among 
the groups Kruskal 
Wallis test 
2=0.500 
P=0.919 
2=1.963 
P=0.580 
2=4.209 
P=0.240 
2=12.743 
P=0.005 
 
Table 6: Angamard 
Groups Score BT F1 F2 AT Within the group 
comparison 
Friedman Test 
No. of 
pt. 
% No. of 
pt. 
% No. 
of pt. 
% No. 
of pt. 
% 
A 0 0 0.0 0 0.0 0 0.0 1 7.7 2=33.393 
p=0.000 1 0 0.00 0 0.00 8 61.5 10 76.9 
2 5 38.5 11 84.6 5 38.5 2 15.4 
3 8 61.5 2 15.4 0 0.00 0 0.00 
B 0 0 0.00 0 0.00 0 0.00 5 41.7 2=32.528 
p=0.000 1 0 0.00 1 8.3 6 50.0 7 58.3 
2 4 33.3 9 75.0 6 50.0 0 0.00 
3 8 66.7 2 16.7 0 0.00 0 0.00 
C 0 0 0.00 0 0.00 0 0.00 8 61.5 2=35.410 
p=0.000 1 0 0.00 1 7.7 11 84.6 5 38.5 
2 6 46.2 12 92.3 2 15.4 0 0.00 
3 7 53.8 0 0.00 0 0.00 0 0.00 
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D 0 0 0.00 0 0.00 0 0.00 6 46.2 2=35.690 
p=0.000 1 0 0.00 0 0.00 9 69.2 6 46.2 
2 5 38.5 11 84.6 4 30.8 1 7.7 
3 8 61.5 2 15.4 0 0.00 0 0.00  
 
 
Inter group 
comparison among 
the groups Kruskal 
Wallis test 
2=0.434 
P=0.933 
2=2.980 
P=0.395 
2=3.507 
P=0.320 
2=9.486 
P=0.023 
Table 7: Aruchi 
Group Score BT F1 F2 AT Within the group 
comparison 
Friedman Test 
No. 
of pt. 
% No. of 
pt. 
% No. of 
pt. 
% No. of 
pt. 
% 
 A 0 0 0.00 0 0.00 0 0.00 1 7.7 2=33.491 
p=0.000 1 0 0.00 0 0.00 4 30.8 10 76.9 
2 4 30.8 9 69.2 9 69.2 2 15.4 
3 9 69.2 4 30.8 0 0.00 0 0.00 
 B 0 0 0.00 0 0.00 0 0.00 3 25.0 2=35.292 
p=0.000 1 0 0.00 0 0.00 6 50.0 6 50.0 
2 4 33.3 8 66.7 6 50.0 3 25.0 
3 8 66.7 4 33.3 0 0.00 0 0.00 
 C 0 0 0.00 0 0.00 0 0.00 9 69.2 2=36.328 
p=0.000 1 0 0.00 3 23.1 8 61.5 4 30.8 
2 5 38.5 9 69.2 5 38.5 0 0.00 
3 8 61.5 1 7.7 0 0.00 0 0.00 
 D 0 0 0.00 0 0.00 0 0.00 6 46.2 2=35.043 
p=0.000 1 0 0.00 2 15.4 7 53.8 7 53.8 
2 5 38.5 10 76.9 6 46.2 0 0.00 
3 8 61.5 1 7.7 0 0.00 0 0.00 
Inter group 
comparison among 
the groups Kruskal 
Wallis test 
2=0.246 
P=0.970 
2=8.318 
P=0.040 
2=2.621 
P=0.454 
2=13.049 
P=0.005 
 
 
Table 8: Trishna 
Group Score BT F1 F2 AT Within the group 
comparison 
Friedman Test 
No. of 
pt. 
% No. of 
pt. 
% No. of 
pt. 
% No. of 
pt. 
% 
A 0 0 0.00 0 0.00 0 0.00 1 7.7 2=32.135 
p=0.000 1 0 0.00 0 0.00 6 46.2 10 76.9 
2 6 46.2 10 76.9 6 46.2 2 15.4 
3 7 53.8 3 23.1 1 7.7 0 0.00 
B 0 0 0.00 0 0.00 0 0.00 3 25.0 2=32.654 
p=0.000 1 0 0.00 0 0.00 8 66.7 9 75.0 
2 4 33.3 9 75.0 4 33.3 0 0.00 
3 8 66.7 3 25.0 0 0.00 0 0.00 
C 0 0 0.00 0 0.00 2 15.4 9 69.2 2=35.154 
p=0.000 1 0 0.00 3 23.1 8 61.5 4 30.8 
2 6 46.2 9 69.2 3 23.1 0 0.00 
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3 7 53.8 1 7.7 0 0.00 0 0.00 
D 0 0 0.00 0 0.00 1 7.7 8 61.5 2=34.342 
p=0.000 1 0 0.00 4 30.8 11 84.6 5 38.5 
2 7 53.8 8 61.5 1 7.7 0 0.00 
3 6 46.2 1 7.7 0 0.00 0 0.00 
Inter group 
comparison among 
the groups Kruskal 
Wallis test 
2=1.063 
P=0.786 
2=8.029 
P=0.045 
2=8.111 
P=0.044 
2=15.054 
P=0.002 
 
Table 9: Alasya 
Group Score BT F1 F2 AT Within the group 
comparison 
Friedman Test 
No. 
of pt. 
% No. of 
pt. 
% No. of 
pt. 
% No. of 
pt. 
% 
 A 0 0 0.00 0 0.00 0 0.00 3 23.1 t =30.961 
p=0.000 1 0 0.00 3 23.1 8 61.5 7 53.8 
2 6 46.2 8 61.8 4 30.8 3 23.1 
3 7 53.8 2 15.4 1 7.7 0 0.00 
 B 0 0 0.00 0 0.00 0 0.00 2 16.7 t =30.360 
p=0.000 1 0 0.00 1 8.3 5 41.7 7 58.3 
2 5 41.7 8 66.7 7 58.3 3 25.0 
3 7 58.3 3 25.0 0 0.00 0 0.00 
 C 0 0 0.00 0 0.00 0 0.00 9 69.2 t =35.147 
p=0.000 1 1 7.7 4 30.8 11 84.6 4 30.8 
2 4 30.8 6 46.2 2 15.4 0 0.00 
3 8 69.2 3 23.1 0 0.00 0 0.00 
 D 0 0 0.00 0 0.00 0 0.00 6 46.2 t =34.565 
p=0.000 1 0 0.00 2 15.4 9 69.2 6 46.2 
2 4 30.8 9 69.2 4 30.8 1 7.7 
3 9 69.2 2 15.4 0 0.00 0 0.00  
Inter group 
comparison among 
the groups Kruskal 
Wallis test 
2=0.650 
P=0.885 
 
2=1.218 
P=0.749 
2=4.993 
P=0.172 
2=10.507 
P=0.015 
Table 10: Gaurav 
Group Score BT F1 F2 AT Within the 
group 
comparison 
Friedman Test 
No. 
of pt. 
% No. 
of pt. 
% No. 
of pt. 
% No. 
of pt. 
% 
A 0 0 0.00 0 0.00 0 0.00 0 0.00 2=32.215 
p=0.000 1 0 0.00 0 0.00 4 30.8 11 84.6 
2 4 30.8 10 76.9 9 69.2 2 15.4 
3 9 69.2 3 23.1 0 0.00 0 0.00 
B 0 0 0.00 0 0.00 0 0.00 3 25.0 2=30.240 
p=0.000 1 0 0.00 1 8.3 4 33.3 6 50.0 
2 4 33.3 8 66.7 8 66.7 3 25.0 
3 8 66.7 3 25.0 0 0.00 0 0.00 
C 0 0 0.00 0 0.00 2 15.4 10 76.9 2=305.462 
p=0.000 1 0 0.00 2 15.2 9 69.2 3 23.1 
AYUSHDHARA, 2019;6(4):2286-2304 
 AYUSHDHARA | July - August 2019 | Vol 6 | Issue 4  2296 
2 7 53.8 11 84.6 2 15.4 0 0.00 
3 6 46.2 0  0 0.00 0 0.00 
D 
 
0 0 0.00 0 0.00 1 7.7 6 46.2 2=33.956 
p=0.000 1 0 0.00 2 15.4 8 61.5 7 53.8 
2 6 46.2 10 76.9 4 30.8 0 0.00 
3 7 53.8 1 7.7 0 0.00 0 0.00 
Inter group 
comparison 
among the groups 
Kruskal Wallis test 
2=1.844 
P=0.605 
2=5.617 
P=0.132 
2=12.070 
P=0.007 
2=17.837 
P=0.000 
 
Table 11: Jwara 
Group  Score BT F1 F2 AT Within the group 
comparison 
Friedman Test 
No. of 
pt. 
% No. of 
pt. 
% No. of 
pt. 
% No. of 
pt. 
% 
A 0 0 0.00 0 0.00 0 0.00 1 7.7 2=29.909 
P=0.000 1 0 0.00 3 23.1 6 46.2 10 76.9 
2 6 46.2 8 61.5 6 46.2 2 15.4 
3 7 53.8 2 15.4 1 7.7 0 0.00 
B 0 0 0.00 0 0.00 0 0.00 3 25.0 2=29.722 
P=0.000 1 0 0.00 4 33.3 7 58.3 9 75.0 
2 8 66.7 8 66.7 5 41.7 0 0.00 
3 4 33.7 0 0.00 0 0.00 0 0.00 
C 0 0 0.00 1 7.7 6 46.2 9 69.2 2=31.660 
P=0.000 1 2 15.4 8 61.5 6 46.2 4 30.8 
2 8 61.5 4 30.8 1 7.7 0 0.00 
3 3 23.1 0 0.00 0 0.00 0 0.00 
D 0 0 0.00 0 0.00 1 7.7 4 30.8 2=31.800 
p=0.00 1 0  5 38.5 9 69.2 9 69.2 
2 8 61.5 7 53.8 3 23.1 0 0.00 
3 5 38.5 1 7.7 0 0.00 0 0.00 
Inter group 
comparison 
among the groups 
Kruskal Wallis test 
2=4.038 
P=.257 
2=7.609 
P=0.55 
2=14.408 
P=0.002 
2=13.061 
P=0.005 
Table 12: Apaka 
Group Score BT F1 F2 AT Within the group 
comparison 
Friedman Test 
No. 
of pt. 
% No. 
of pt. 
% No. 
of pt. 
% No. of 
pt. 
% 
A 0 0 0.00 0 0.00 0 0.00 1 7.7 2=30.083 
p=0.000 1 0 0.00 2 15.4 5 38.5 10 76.9 
2 6 46.2 9 69.2 8 61.5 2 15.4 
3 7 53.8 2 15.4 0 0.00 0 0.00 
B 0 0 0.00 0 0.00 0 0.00 4 33.3 2=25.105 
p=0.000 1 1 8.3 6 50.0 8 66.7 6 50.0 
2 7 58.3 3 25.0 3 25.0 2 16.7 
3 4 33.3 3 25.0 1 8.3 0 0.00 
C 0 0 0.00 1 7.7 6 46.2 10 76.9 2=31.088 
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1 6 46.2 10 76.9 7 53.8 3 23.1 p=0.000 
2 7 53.8 2 15.4 0 0.00 0 0.00 
3 0 0.00 0 0.00 0 0.00 0 0.00 
D 0 0 0.00 0 0.00 4 30.8 8 61.5 2=31.702 
p=0.000 1 4 30.8 10 76.9 9 69.2 5 38.5 
2 7 53.8 3 23.1 0 0.00 0 0.00 
3 2 15.4 0 0.00 0 0.00 0 0.00 
Inter group 
comparison among 
the groups Kruskal 
Wallis test 
2=15.714 
P=0.001 
2=15.549 
P=0.001 
2=22.971 
P=0.000 
2=15.359 
0.002 
Table 13: Hemoglobin 
Group Hb (Mean±SD) Within the group comparison 
Paired t test (BT-AT) BT F1 F2 AT 
A 11.353± 
1.661 
11.120± 
1.5392 
11.468± 
1.6034 
12.09± 
1.576 
t=2.398 
p=0.034 
B 11.450± 
1.5548 
11.725± 
1.3308 
12.233± 
1.1625 
12.67 
±1.366 
t=-5.104 
p=0.000 
C 10.977± 
1.914 
11.708± 
2.1566 
12.062± 
1.5196 
12.45 
±1.187 
t=-4.351 
p=0.001 
D  11.038± 
1.2413 
10.92± 
1.1415 
10.78± 
1.2121 
10.46 
±1.015 
t=-7.129 
p=0.041 
Between the group 
comparison One-
way ANOVA Test 
F=0.261 
P=0.853 
F=0.303 
P=0.134 
F=0.567 
P=0.499 
F=0.776 
P=0-513 
 
Table 14: TLC 
Group TLC (Mean±SD) Within the group comparison 
Paired t test (BT-AT) BT F1 F2 AT 
A 6.93± 
3.36 
6.52± 
2.38 
6.35± 
1.86 
6.5± 1.70 t=0.580 
p=0.573 
B 6.69± 
2.06 
7.55± 
2.24 
7.64± 
1.93 
7.5± 1.64 t=-3.395 
p=0.006 
C 7.09± 
1.58 
7.44± 
1.65 
6.85± 
1.64 
7.00± 
1.97 
t=-0.158 
p=0.877 
D  6.79± 
1.79 
6.83± 
1.62 
6.92± 
1.57 
7.26± 
1.74 
t=-2.332 
p=0.038 
Between the group 
comparison Kruskal 
Wallis test 
2=0.714 
P=0.870 
2=2.299 
P=0.513 
2=2.681 
P=0.443 
2=1.379 
P=0.710 
 
Table 15: Platelet 
Group Platelet (Mean±SD) Within the group comparison 
Paired t test (BT-AT) BT F1 F2 AT 
A 191.92 
±57.799 
192.85 
±54.516 
185.82 
±56.138 
197.57 
±54.360 
t=-1.227 
p=0.243 
B 190.33 
±36.252 
191.72 
±31.908 
199.75 
±36.197 
202.88 
±36.344 
t=-4.691 
p=0.001 
C 203.31 
±93.298 
205.22 
±89.949 
215.68 
±91.633 
233.54 
±88.833 
t=-2.593 
p=0.024 
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D  191.28 
±50.520 
197.69 
±52.938 
202.28 
±61.314 
215.38 
±75.585 
t=-1.650 
p=0.125 
Between the group 
comparison One-way 
ANOVA Test 
F=0.119 
P=0.949 
F=0.127 
P=0.943 
F=0.461 
P=0.422 
F=0.725 
P=0.542 
 
Table 16: RBS 
Group RBS (Mean±SD) Within the group comparison 
Paired t test (BT-AT) BT F1 F2 AT 
A 126.400
±20.32 
126.85±
15.14 
122.23±
14.77 
123.88±
17.03 
t=0.618 
p=0.548 
B 119.525
±24.77 
123.58±
26.77 
124.00±
50.18 
152.71±
47.63 
t=-2.076 
p=0.062 
C 114.669
±32.25 
118.17±
25.04 
115.07±
37.00 
126.33±
23.12 
t=-1.734 
p=0.108 
D  127.769
±7.417 
124.95 
±6.76 
126.50 
±9.15 
129.48±
10.40 
t=-0.558 
p=0.587 
Between the group 
comparison One-way 
ANOVA Test 
F=0.917 
P=0.440 
F=0.454 
P=0.716 
F=0.307 
P=0.820 
F=2.807 
P=0.050 
 
Post Hoc Test 
A vs B    P=0.013  
B vs C    P=0.022  
B vs D    P=0.042  
Table 17: SGOT 
Group SGOT (Mean±SD) Within the group comparison 
Paired t test (BT-AT) BT F1 F2 AT 
A 33.20± 
23.26 
31.57± 
20.24 
29.86± 
16.01 
30.42± 
15.81 
t=1.062 
p=0.309 
B 30.53± 
14.24 
28.43± 
11.45 
27.97± 
9.85 
28.53± 
9.30 
t=1.049 
p=0.317 
C 25.33± 
10.47 
23.93± 
8.43 
24.10± 
6.87 
25.15± 
6.36 
t=0.105 
p=0.918 
D  23.00± 
7.51 
21.55± 
5.53 
22.04± 
5.130 
22.73± 
5.25 
t=0.299 
p=0.770 
Between the group 
comparison Kruskal 
Wallis test 
2=2.041 
P=0.564 
2=2.846 
P=0.416 
2=2.722 
P=0.427 
2=3.005 
P=0.391 
 
Table 18: SGPT 
Group SGPT (Mean±SD) Within the group comparison 
Paired t test (BT-AT) BT F1 F2 AT 
A 42.05± 
28.35 
42.98± 
27.04 
45.45± 
83.60 
40.00± 
17.50 
t=0.517 
p=0.614 
B 33.77± 
18.27 
33.01± 
16.32 
33.32± 
15.07 
33.990± 
14.54 
t=-0.152 
p=0.882 
C 28.02± 
17.07 
28.96± 
12.43 
30.48± 
12.87 
29.690± 
11.74 
t=0.699 
p=0.498 
D 23.56± 
5.02 
23.30± 
3.71 
23.75± 
4.50 
24.57± 
4.41 
t=-1.417 
p=0.182 
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Between the group 
comparison Kruskal 
Wallis test 
2=5.984 
P=0.112 
2=8.471 
P=0.037 
2=9.543 
P=0.023 
2=10.090 
P=0.018 
 
Post Hoc Test 
A vs C  P=/0.042 P=/0.046 P=/0.048  
A vs D P=/0.014 P=/0.005 P=/0.018 P=/0.004  
Table 19: Direct bilirubin 
Group Direct bilirubin (Mean±SD) Within the group comparison 
Paired t test (BT-AT) BT F1 F2 AT 
A 0.3962 
±0.28342 
0.4554 
±0.21030 
0.4708 
±0.33062 
0.4269 
±0.26164 
t=-0.284 
P=0.781 
B 0.4675 
±0.43766 
0.3642 
±0.26603 
0.4308 
±0.39730 
0.4300 
±0.26031 
t=-0.224 
P=0.827 
C 0.2162 
±0.14431 
0.4308 
±0.28863 
0.4100 
±0.34271 
0.4908 
±0.28652 
t=-2.747 
P=0.018 
D  0.3308 
±0.13775 
0.4654 
±0.33014 
0.5131 
±0.28188 
0.4623 
±0.24574 
t=-1.520 
P=0.154 
Between the group 
comparison 
Kruskal Wallis test 
2=6.928 
P=0.074 
2=1.905 
P=0.592 
2=2.140 
P=0.544 
2=1.058 
P=0.787 
 
Table 20: Urea 
Group Urea (Mean±SD) Within the group comparison 
Paired t test (BT-AT) BT F1 F2 AT 
A 25.577 
±8.6066 
27.8985 
±8.34488 
29.1162 
±9.00886 
28.99 
±8.065 
t=-3.322 
P=0.006 
B 19.950 
±4.7769 
20.6167 
±4.64383 
21.1750 
±4.58458 
21.90 
±4.923 
t=-5.649 
P=0.000 
C 26.400 
±14.6255 
27.0231 
±11.06520 
28.1385 
±11.27812 
27.74± 
11.552 
t=-0.697 
P=0.499 
D 40.500 
±6.9162 
41.3077 
±6.37619 
43.2692 
±6.94855 
45.27 
±6.879 
t=-8.644 
P=0.000 
Between the group 
comparison One 
way ANOVA test 
F=10.668 
P=0.000 
F=14.849 
P=0.000 
F=15.426 
P=0.000 
F=18.657 
P=0.000 
 
Post Hoc Test 
A vs B  P=0.028 P=0.022 P=0.037  
A vs D P=0.000 P=0.000 P=0.000 P=0.000  
B vs C   P=0.044   
B vs D P=0.000 P=0.000 P=0.000 P=0.000  
C vs D P=0.000 P=0.000 P=0.000 P=0.000  
Table 21: Creatinine 
Group Creatinine (Mean±SD) Within the group comparison 
Paired t test (BT-AT) BT F1 F2 AT 
A 0.8246 
±0.34594 
0.8915 
±0.30542 
0.7238± 
0.25138 
0.9123± 
0.27776 
t=-0.731 
P=0.479 
B 0.8083 
±0.25715 
0.7342 
±0.29296 
0.7750± 
0.24612 
0.7333± 
0.23094 
t=0.641 
P=0.535 
C 0.7992 0.8638 0.9062± 0.8185± t=-0.235 
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±0.23722 ±0.33278 0.33503 0.25570 P=0.818 
D 0.6769 
±0.35392 
0.6200 
±0.22672 
0.7238± 
0.23712 
0.7823± 
0.16604 
t=-0.980 
P=0.347 
Between the group 
comparison One 
way ANOVA test 
F=0.642 
P=0.592 
F=2.388 
P=0.081 
F=1.313 
P=0.281 
F=1.294 
P=0.288 
 
Table 22: Cholesterol 
Group Cholesterol (Mean±SD) Within the group comparison 
Paired t test (BT-AT) BT F1 F2 AT 
A 170.50 
±16.939 
171.37 
±16.923 
171.98 
±17.274 
171.74 
±16.448 
t=-1.195 
P=0.285 
B 162.48 
±34.159 
166.17 
±33.324 
176.20 
±50.056 
187.40 
±61.563 
t=-2.410 
P=0.035 
C 164.83 
±47.647 
161.11 
±34.127 
164.70 
±36.441 
164.14 
±31.1248 
t=-0.099 
P=0.923 
D  166.85 
±38.390 
168.21 
±36.612 
170.69 
±36.652 
173.30 
±36.1399 
t=-4.524 
P=0.001 
Between the group 
comparison One way 
ANOVA test 
F=0.112 
P=0.953 
F=0.248 
P=0.863 
F=0.211 
P=0.888 
F=0.211 
P=0.524 
 
Table 23: HDL 
Group HDL (Mean±SD) Within the group comparison 
Paired t test (BT-AT) BT F1 F2 AT 
A 46.51 ± 
15.840 
45.87 ± 
14.931 
48.06 ± 
15.779 
49.41 ± 
14.698 
t=-1.731 
P=0.479 
B 51.60 ± 
10.103 
50.33 
±8.738 
52.79 
±8.212 
55.42 
±7.171 
t=0.641 
P=0.535 
C 52.26 ± 
16.570 
50.70 ± 
13.580 
50.25 
±10.34 
48.73 
±8.788 
t=-0.235 
P=0.818 
D  53.38 ± 
12.278 
54.45 
±9.963 
55.42 
±8.51 
56.88 
±7.863 
t=-0.980 
P=0.347 
Between the group 
comparison One way 
ANOVA test 
F=0.611 
P=0.611 
F=1.089 
P=0.363 
F=1.047 
P=0.380 
F=2.144 
P=0.107 
 
Table 24: Anti CCP 
Group Anti CCP (Mean±SD) Within the group comparison  
Wilcoxon Signed Rank test BT AT 
A 76.55± 
160.088 
70.33± 
146.357 
Z=-2.758 
P=0.006 
B 74.94± 
163.620 
49.97± 
93.868 
Z=-2.293 
P=0.022 
C 131.03± 
140.061 
87.62± 
98.557 
Z=-3.111 
P=0.002 
D  52.86± 
13.356 
26.41± 
7.419 
Z=-3.181 
P=0.001 
Between the group comparison 
Kruskal Wallis test 
2=15.461 
P=0.001 
2=7.303 
P=0.063 
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Table 25: RA 
Group RA (Mean±SD) Within the group comparison  
Wilcoxon Signed Rank test BT AT 
A 59.70± 
109.735 
57.883± 
106.7949 
Z=-1.992 
P=0.046 
B 64.36± 39.344 45.208± 
22.3579 
Z=-2.347 
P=0.019 
C 80.42± 46.740 69.262± 
83.1046 
Z=-2.040 
P=0.041 
D  77.77± 16.146 47.308± 
18.7189 
Z=-3.184 
P=0.001 
Between the group comparison 
Kruskal Wallis test 
2=6.650 
P=0.084 
2=2.845 
P=0.416 
 
Discussion on Therapeutic Profile 
Pain[15]- From the statistical evaluation, it is 
concluded that Inter group comparison showed 
significant changes at all the follow up. Within the 
group showed highly significant changes in all the 
groups. The treatment response of the groups 
according to relief in pain significantly observed 
was in Group D (61.5%) followed by Group C 
(38.5%). 
It may be due to Ushna virya property of drug like 
Shunthi, Guduchi, Trivrit help in Ama pachan, 
thereby reducing pain. This may be due to 
decreased PGE2 release inside the joint space. 
Swelling[16]- From the statistical evaluation, it is 
concluded that Inter group comparison showed 
significant changes at all the follow up. Within the 
group showed highly significant changes in all the 
groups. The treatment response of the groups 
according to relief in swelling significantly observed 
was in Group D (61.5%) followed by Group A 
(23.1%). Swelling occurs due to predominance of 
VK Dosha. Therefore the drug like Vibhitaki, 
Haritaki, Guduchi having Ushna virya property, 
thereby reducing the swelling. This relief in 
swelling may be due to inhibition of IL-1, IL-6 and 
TNF-α. 
Joint stiffness[17]- From the statistical evaluation, it 
is concluded that Intergroup comparison showed 
significant changes at all the follow up. Within the 
group showed highly significant changes in all the 
groups. The treatment response of the groups 
according to relief in joint stiffness significantly 
observed was in Group C and Group D are equal 
(38.5%) followed by Group B (16.7%) and Group A 
(7.7%). Joint stiffness occurs due to predominance 
of Vata Dosha. Therefore Vatahara drug like Trivit, 
Shunthi having Ushna property, thereby reducing 
joint stiffness. 
Walking Time[18]- From the statistical evaluation, it 
is concluded that Inter group comparison showed 
significant changes at all the follow up. Within the 
group showed highly significant changes in all the 
groups. The treatment response of the groups 
according to relief in walking time significantly 
observed was in Group C and Group D are equal 
(76.9%) followed by Group B (33.3%) and Group A 
(7.7%). 
Morning stiffness is the common manifestation in 
RA. After receiving treatment by the patients there 
will be reduction in joint stiffness, thereby 
enhancing the walking time. As per Ayurvedic text, 
Vasti is said to be the major procedure to reduce 
Vata and stiffness is mainly related to Vata Dosha. 
That is why those patients who receive Vasti show 
better result. 
Grip power[19]- From the statistical evaluation, it is 
concluded that Intergroup comparison showed 
significant changes at all the follow up. Within the 
group showed highly significant changes in all the 
groups. The treatment response of the groups 
according to relief in grip power significantly 
observed was in Group C and Group D are equal 
(53.8%) followed by Group B (8.3%) and Group A 
(7.7%). Administration of Vasti pacified Vata Dosha, 
thereby enhancing grip power. 
Angamarda[20]- From the statistical evaluation, it is 
concluded that Inter group comparison showed 
significant changes at all the follow up. Within the 
group showed highly significant changes in all the 
groups. The treatment response of the groups 
according to relief in Angamard significantly 
observed was in Group C (61.5%) followed by 
Group D (46.2%), Group B (41.7%) and Group A 
(7.7%). Ama is the causative factor of Amavata. 
Kaphahara property of drugs like Amalaki, Vibhitaki 
reduces the Ama and hence gets relief from 
Angamarda. 
Aruchi[21]- From the statistical evaluation, it is 
concluded that Inter group comparison showed 
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significant changes at all the follow up. Within the 
group showed highly significant changes in all the 
groups. The treatment response of the groups 
according to relief in Aruchi significantly observed 
was in Group C (69.2%) followed by Group D 
(53.8%), Group B (25%) and Group A (7.7%). 
Aruchi occurs due to vitiation of Kapha Dosha. After 
receiving treatment by Ushna Virya property like 
Shunthi, Vibhitaki produce Ruchikar effect. 
Trishna[22] - From the statistical evaluation, it is 
concluded that Inter group comparison showed 
significant changes at all the follow up. Within the 
group showed highly significant changes in all the 
groups. The treatment response of the groups 
according to relief in Trishna significantly observed 
was in Group C (69.2%) followed by Group D 
(61.5%), Group B (25%) and Group A (7.7%). It 
occurs due to Vata Pitta Dosha. In order to reduce 
the Trishna drug like Lajjalu, Gokshur having Shita 
virya property and Vata pitta shamak nature they 
reduces Trishana. 
Alasya[23] - From the statistical evaluation, it is 
concluded that Inter group comparison showed 
significant changes at all the follow up. Within the 
group showed highly significant changes in all the 
groups. The treatment response of the groups 
according to relief in Alashya significantly observed 
was in Group C (69.2%) followed by Group D 
(46.2%), Group A (23.1%) and Group B (16.7%). It 
occurs due to Kapha Dosha. After receiving 
treatment by Ushna virya drug like Shunthi, Guduchi 
reduces Kapha Dosha and ultimately reduces 
Alasya. 
Gaurav[24]- From the statistical evaluation, it is 
concluded that Inter group comparison showed 
significant changes at all the follow up. Within the 
group showed highly significant changes in all the 
groups. The treatment response of the groups 
according to relief in Gaurav significantly observed 
was in Group C (76.9%) followed by Group D 
(46.2%) and Group B (25%). 
It occurs due to Ama Dosha. After receiving 
treatment by Ushna Virya drug like Shunthi, 
Guduchi, Trivrit reduces Ama Dosha and ultimately 
reduces Gaurav. 
Jwara[25]- From the statistical evaluation, it is 
concluded that Inter group comparison showed 
significant changes at all the follow up. Within the 
group showed highly significant changes in all the 
groups. The treatment response of the groups 
according to relief in Jwara is significantly observed 
was in Group C (69.2%) followed by Group D 
(30.8%), Group B (25%) and Group A (7.7%). It 
occurs due to Pitta Dosha. After receiving treatment 
by Shita Virya drug like Gokshura, Lajjalu reduces 
Pitta Dosha and ultimately reduces Jwara. 
Apaka[26] - From the statistical evaluation, it is 
concluded that Inter group comparison showed 
significant changes at all the follow up. Within the 
group showed highly significant changes in all the 
groups. The treatment response of the groups 
according to relief in Apaka is significantly observed 
was in Group C (76.9%) followed by Group D 
(61.5%), Group B (33.3%) and Group A (7.7%). 
It occurs due to Ama Dosha. After receiving 
treatment by Ushna Virya drug like Haritaki, 
Guduchi, Trivrit reduces Ama Dosha and ultimately 
reduces Apaka. 
Discussion on Laboratory Parameter 
There is no significant change were 
observed in Haemoglobin, Total Leucocyte Count, 
Random Blood Sugar, Serum Glutamic Pyruvic 
Transaminase (SGPT), Serum Glutamic Oxaloacetic 
Transaminase (SGOT), Creatinine and Urea after 
treatment in all four groups.  
Anti CCP[27] 
The assessment of response of drug 
treatment showed that, in group A- initial mean was 
76.55±160.088 and changed to 70.33±146.357. In 
group-B- initial mean was 74.94±163.620 and 
changed to 49.97±93.868 after treatment. In group-
initial mean was 131.03±140.061 and changed to 
87.62±98.557 whereas in group-D, initial mean was 
52.86±13.356 and changed to 26.41±7.419 after 
treatment. There was a significant reduction in 
Anti-CCP in all groups. It may be due to reduction in 
inflammation of disease. Macrophage migration 
inhibitory factor (MIF) and vascular endothelial 
growth factor, as crucial parameter of angiogenesis 
and inflammation, were evaluated to identify the 
role of cyclic citrullinated peptic antibodies (Anti 
ccp) during angiogenesis in rheumatoid arthritis. 
Rheumatoid Arthritis [28] 
The assessment of response of drug 
treatment showed that, in group-1 initial mean was 
59.70± 109.735 and changed to 57.883±106.794. 
Then after treatment, In group-B, initial mean was 
64.36±39.344 and changed to 45.208±22.3579 after 
treatment. In group-C, initial mean was 80.42 
±46.740 and changed to 69.262±83.1046 whereas 
in group-D, initial mean was 77.77±16.146 and 
changed to 47.308±18.7189 after treatment. There 
was a significant reduction in RA factor titre in all 
groups. It may be due to breaking of pathogenesis of 
disease by Srotosodhan property of Matra Vasti. 
IgM, IgG, IgA isotype of RF factor occur in sera from 
patients with RA, although the IgM isotype is the 
one most frequently measured by commercial 
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laboratories. Serum IgM RF has been found in 75-
80% of patients with RA; therefore, a negative 
result does not exclude the presence of disease. It is 
also found in other connective tissue, such as 
primary Sjogrens systemic lupus erythematosus, 
Hepatitis B and C and in chronic infection. 
EULAR 
The assessment of response of drug 
treatment showed that, in group- A initial mean was 
8.31±1.82 and changed to 6.77±0.725 after 
treatment. In group-B, initial mean was 7.92±1.379 
and changed to 5.83±1.030 after treatment. In 
group-C, initial mean was 7.62±1.446 and changed 
to 5.15±1.068 whereas in group-D, initial mean was 
7.46±1.330 and changed to 5.31±1.032 after 
treatment. The maximum number of points possible 
is 10. A classification of definitive RA requires a 
score of 6/10 or higher. Patients with a score lower 
than 6/10 should be reassessed over time. Overall 
effect of therapy was excellent in group C in which 
Alambushadi churna and Matra vasti were 
combined given to the patients. In group B only 
Matra Vasti was used which showed good result. 
Effect of Alambushadi churn in patient of Group A 
was also good. Lastly, patients under group D who 
were on Methotrexate 5mg 1OD per week had the 
good improvement followed by Folic acid 5mg ODS. 
CONCLUSION 
On evaluation of the knowledge of the literature and 
experience of the present work it may be concluded, 
that 
 Disease Amavata can be correlated to 
Rheumatoid Arthritis, which is one among the 
chronic destructive polyarthritic systemic 
disease. 
 The exact etiology of the disease remains 
unknown, but the pathognomic Nidana like Ama 
is believed to be acts as autoantigen, which 
triggers the immunological reaction in 
genetically susceptible individuals. 
Primarily the Samprapti originates in the 
Annavahasrotasa. 
 The disease Amavata is diagnosed on 
symptomatology, specific laboratory tests like 
RF, CRP help in diagnostic and help in 
assessment of treatment given.  
 EULAR 20101 criteria help in the diagnosis of 
RA. 
 Some of the Pravriddha Amavata Laxana and 
Upadravas can be considered as the extra-
articular manifestations of Amavata (RA). 
 As the disease is genetic and autoimmune in 
origin the permanent complete remission is not 
possible. 
 The sign and symptoms e.g., Loss of appetite, 
Angamarda, Alasya etc. due to derangement of 
Aamare observed to be improved in by 
Alambushadi churn oral and Matra Vasti regime 
as compared to Methotrexate. 
 There was neither any side effect produced nor 
any side effect observed during the trial drug 
therapy. 
We have observed that in group C oral 
intake of Alambushadi churna and Matra vasti by 
Dwipanchmuladhya taila is effective in treating all 
the sign and symptoms and other associated 
Lakshanas of the disease. 
So we feel immense pleasure in declaring 
highly encouraging results of the research work and 
can say that the Ayurvedic management schedule of 
Matra vasti and Alambushadi churna can be used in 
the chronic as well as acute patients of Amavata 
with fruitful results. 
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